Physician profile
Mohammad Sheikh
NPI 1588308456
$989.51
in general payments reported to CMS, 2019-2025
16 companies · $990 in 2025
The $990 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $990.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $990.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $989.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $224.34 | 2025 | |
| Emd Serono, INC. | $173.07 | 2025 | Mavenclad |
| Novartis Pharmaceuticals Corporation | $90.62 | 2025 | |
| Biogen, INC. | $65.73 | 2025 | Spinraza, Qalsody |
| Genzyme Corporation | $64.95 | 2025 | |
| Argenx US, INC. | $64.11 | 2025 | Vyvgart, Vyvgart Hytrulo |
| Sk Life Science, INC. | $47.75 | 2025 | |
| Livanova USA, INC. | $43.09 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Neurelis, INC. | $41.10 | 2025 | Valtoco |
| Jazz Pharmaceuticals INC. | $38.19 | 2025 | |
| Tg Therapeutics, INC. | $32.57 | 2025 | |
| Ani Pharmaceuticals, INC. | $22.97 | 2025 | Purified Cortrophin Gel |
| Merz Pharmaceuticals, LLC | $21.34 | 2025 | Xeomin, Inbrija, Ampyra |
| Mallinckrodt Hospital Products INC. | $20.49 | 2025 | Acthar |
| Astrazeneca Pharmaceuticals Lp | $20.45 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $18.74 | 2025 | Uplizna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Sheikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.